US FDA approves fenfluramine (Fintepla) for treatment of seizures associated with Dravet syndrome in patients age 2 and older

Approval was based on two studies (total n=202) which showed patients treated with fenfluramine had significantly greater reductions in frequency of convulsive seizures vs. placebo within 3-4 weeks; and remained generally consistent over the 14 to 15 week treatment periods.


US Food and Drug Administration